Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ascletis Pharma, Inc. ( (HK:1672) ) has issued an announcement.
Ascletis Pharma Inc. has announced its 2025 Annual General Meeting, scheduled for May 22, 2025, in Hangzhou, China. The meeting will address several key business items, including the consideration of the company’s audited financial statements for 2024, the re-election of directors, and the re-appointment of KPMG as the auditor. Additionally, resolutions will be proposed to authorize the company’s board to manage share allotments and repurchases, potentially impacting the company’s capital structure and shareholder value.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing innovative drugs for the treatment of liver diseases, viral infections, and cancer. The company is listed on the Hong Kong Stock Exchange.
YTD Price Performance: 108.64%
Average Trading Volume: 7,620,590
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.09B
For an in-depth examination of 1672 stock, go to TipRanks’ Stock Analysis page.